• About
  • Privacy Policy
  • Terms
  • Contact
Friday, January 27, 2023
Financial Eye News
  • Home
  • Markets
    • Stock Market News
    • Commodities
    • Forex
    • Renewables
  • Cryptocurrency
    • Ultimate Guide to Crypto
  • Business
    • News
    • Companies
    • Technology
    • Climate
    • Politics
  • Reports
    • Ultimate Guide to Crypto
  • VideosNew
No Result
View All Result
  • Home
  • Markets
    • Stock Market News
    • Commodities
    • Forex
    • Renewables
  • Cryptocurrency
    • Ultimate Guide to Crypto
  • Business
    • News
    • Companies
    • Technology
    • Climate
    • Politics
  • Reports
    • Ultimate Guide to Crypto
  • VideosNew
No Result
View All Result
Financial Eye News
No Result
View All Result

Blood testing start-up Osler to tap investors as it primes device launch

March 21, 2022
in Technology
Reading Time: 3 mins read
49 2
ADVERTISEMENT

Osler Diagnostics is planning to raise more funds as the Oxford university spinout prepares to launch its first blood-testing device, in an industry tarnished by its most famous forerunner: Theranos.

The diagnostics start-up, co-founded by 27-year-old Connor Campbell, who attended but did not finish medical school, has already raised $100mn in the five years since its launch.

While the group is named after famed 19th-century diagnostician Sir William Osler, its tabletop device has a sleek iPad-like interface.

Campbell hopes the portable diagnostic will transform healthcare by offering a range of fast, cheap tests outside the laboratory, sometimes from just a few drops of blood.

But he is keen to stress that any comparison with Theranos, the Silicon Valley start-up whose co-founder Elizabeth Holmes was recently convicted of fraud, stops there.

“Theranos started from an idea of Elizabeth Holmes. We started based on decades of research from Oxford university from the most successful departments in the history of diagnostics,” he said.

“They built an organisation that was led by board members who were diplomats, lawyers or generals. We’ve got an organisation filled with experts in their field led by some of the biggest leaders in global diagnostics, global pharma and global life sciences.”

Campbell co-founded Osler with Jason Davis, a chemistry professor at Oxford, where the portable electrochemical blood glucose sensor was created.

This month the company appointed Chris Smith, chief executive of Nasdaq-listed Ortho Clinical Diagnostics to chair the board, and David Berry, general partner at healthcare venture capital firm Flagship Pioneering, as a non-executive director.

Campbell left his medicine course at Oxford after three years to go into business. He ended up working with McKinsey in Sierra Leone at the end of the Ebola crisis, where he saw first-hand the importance of diagnostics.

“To take an extreme example, if you don’t know who’s dying of what, where do you send healthcare resources? What resources do you send?” he said.

He says the pandemic has “hammered home” the point that diagnostics are vital to changing healthcare.

Osler is starting by seeking approval for two critical cardiac tests but hopes its breadth will help it outcompete existing point-of-care diagnostics. Campbell said the device can already conduct a far wider range of tests, including diagnosing infectious diseases. It processes most tests in about 10 minutes.

ADVERTISEMENT

Wearing a white coat over his black Osler-branded T-shirt, Campbell demonstrates the machine in a lab.

Blood samples — collected from a finger with a pinprick or from a vein with a conventional needle — are added into cartridges with all of the reagents necessary to perform a specific test or panel of tests. Inside the machine, the blood is manipulated to prepare the sample, and then presented to a biosensor, which translates a biochemical reaction into measurable data.

Osler will have to prove to regulators through clinical studies that it is substantially equivalent to far larger lab machines.

The company has yet to publish papers on its work in scientific journals, although it has patented innovations at every stage of the process.

Roland Diggelmann, chief executive of device maker Smith & Nephew, who previously led diagnostics for Roche, does not see the lack of publications as a weakness, arguing it is normal for a diagnostics maker to wait until it is applying for regulatory approval to publish.

Diggelmann, who has no financial relationship with Osler, said its technology was “promising” and pointed to the company’s “strong academic background” and ambition to build a large menu of tests.

“The Osler approach is that they basically want to do everything in one device. That is what nobody has been able to crack. That’s a big challenge. They believe they can do this and there is a chance that they can. There is still a lot of work required,” he said.

Despite the long shadow of Theranos, investors are pouring money into companies that promise to revolutionise blood testing.

Osler raised a series B funding of $50mn at the start of last year, led by Oxford Science Enterprises and Bravos Capital. It will begin a series C fundraising shortly. Its investors include business leaders Charles Dunstone, co-founder of Carphone Warehouse, Irish financier Dermot Desmond, and British billionaire Michael Spencer.

Source: Financial Times

Share6Tweet4Share1SendShareSend

Related Posts

Technology

French Pornhub case shows how hard it is to regulate the internet

December 5, 2022
Technology

Covid chaos at Foxconn iPhone plant causes 29% revenue fall

December 5, 2022
Technology

Spiracle is turning niche literary fiction into audiobooks

December 5, 2022
Technology

Elon Musk, Matt Taibbi, and a Very Modern Media Maelstrom

December 5, 2022
Technology

The apps making business more social

December 4, 2022
Technology

Meloni pushes back on Italy’s shift into digital payments age

December 4, 2022

Popular Stories

  • AIG to launch cut-price IPO of life and asset management unit

    48 shares
    Share 19 Tweet 12
  • EY boss targets $10bn boost from Silicon Valley tie-ups after break-up

    32 shares
    Share 13 Tweet 8
  • Tesla delays plan to restore Shanghai output to pre-lockdown levels -memo

    32 shares
    Share 13 Tweet 8
  • TV production giant Banijay to go public via Arnault-backed Spac

    30 shares
    Share 12 Tweet 8
  • Nio to Invest $32.8M Building R&D Labs in Shanghai By Financial Eye

    30 shares
    Share 12 Tweet 8
ADVERTISEMENT

Latest News

Taylor Swift Fans Sue Ticketmaster’s Parent Company

December 5, 2022

Fisker trades down following price cut at Citi By Financial Eye

December 5, 2022

UAW president faces run-off election as reformers make gains

December 5, 2022

Felipe Valls, 89, Whose Cuban Restaurant Became a Political Hub, Dies

December 5, 2022

Longroad buys 98-MW solar farm in California

December 5, 2022
Facebook Twitter LinkedIn

Financial Eye is one of the most trusted news sources for Financial News, global news and local USA news, we provide the news from the most trusted sources.

LEARN MORE »

Recent News

  • Taylor Swift Fans Sue Ticketmaster’s Parent Company
  • Fisker trades down following price cut at Citi By Financial Eye
  • UAW president faces run-off election as reformers make gains

Sections

  • Business
  • Climate
  • Commodities
  • Companies
  • Cryptocurrency
  • Cryptocurrency
  • Forex
  • Green Energy
  • Latest Financial News
  • News
  • Politics
  • Stock Market News
  • Technology
  • Videos

© 2022 Financial Eye News Media

No Result
View All Result
  • Home
  • Markets
    • Stock Market News
    • Commodities
    • Forex
    • Renewables
  • Cryptocurrency
    • Ultimate Guide to Crypto
  • Business
    • News
    • Companies
    • Technology
    • Climate
    • Politics
  • Reports
    • Ultimate Guide to Crypto
  • Videos

© 2022 Financial Eye News Media

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Subscribe To Our Daily News Round-Up.

The top ten most-read stories direct to your inbox

You have Successfully Subscribed!

You have Successfully Subscribed!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.